Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)

Vir Biotechnology, Inc.

VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.
VIR-5500 (PSMA mCRPC): PSA declines in 100% (12/12) and PSA50 response in 58% (7/12) at first dose ≥120 µg/kg.
Safety: No dose-limiting CRS; max grade 2 CRS; MTD not reached for either TCE; dosing up to 1000 µg/kg.
PRO-XTEN masking technology shows minimal systemic unmasking; half-life 6-10 days enabling Q3W dosing.
Phase 1 trials ongoing; dose escalation continues; company to hold investor call Jan 8, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.